Indapta Therapeutics
PrivateLast Round
VC Round
Dec 17, 2024
Total Funding Raised
$54.5M
Company Overview
Indapta Therapeutics is a biotechnology company developing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy platform to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Indapta Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Indapta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 17, 2024 | ||||
| Grant | May 15, 2024 | ||||
| Series A | Feb 10, 2022 |
Key People
Founding team and executive leadership
Indapta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Prevention & Research Institute of Texas | Grant |
| RA Capital Management | VC Round, Series A |
| Vertex Ventures HC | VC Round, Series A |
| Pontifax Venture Capital | VC Round |
| Pontifax Credit | VC Round |
| Cancer Prevention and Research Institute of Texas | Grant |
| Leaps by Bayer | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 17, 2024
$23M raised from Leaps by Bayer and others.
- May 15, 2024
$4.5M grant from Cancer Prevention & Research Institute of Texas
Indapta Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Indapta Therapeutics's valuation, stock price, and market status.